Trending...
- Eddy Corp and SMAART POWER LLC Announce Strategic Teaming Agreement to Accelerate Microgrid and Distributed Energy Deployments - 178
- California: Governor Newsom expands film and TV tax credits with new legislation, creates tax credit to support post-production jobs - 157
- California: Governor Newsom issues legislative update 9.18.26 - 139
SAN DIEGO, Dec. 4, 2020 /PRNewswire/ -- Angiocrine Bioscience Inc., a clinical-stage biopharmaceutical company today announced that they have been selected by the American Society of Hematology (ASH) for an oral presentation on the preliminary results of a Phase 1b/2 study of AB-205 to prevent or reduce severe organ toxicities associated with high-dose therapy followed by autologous hematopoietic cell transplantation used with curative intent in patients with aggressive systemic lymphoma.
"Our investigators and Angiocrine are honored to be selected by ASH to present at its annual meeting this December," commented Paul Finnegan, MD, Angiocrine CEO. "We look forward to Dr. Michael Scordo's presentation of AB-205's efficacy and safety results from our Phase 1b/2 study as well as preparing for the upcoming Phase 3 registration study for this indication."
Session Name: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence I
Session Date: Saturday, December 5, 2020
Session Time: 7:30 AM - 9:00 AM ET
Presentation Time: 7:45 AM ET
About Severe Regimen-Related Toxicities
High-dose therapy and autologous hematopoietic cell transplantation is considered a standard-of-care method to cure aggressive systemic lymphoma. High dose therapy effectively eradicates cancer cells but also damages healthy tissue, which can lead to severe toxicities. Most affected is the lining of the oral-gastrointestinal (GI) tract. The oral GI tract renews its mucosal lining every 3 to 7 days. Because of the collateral damage from high dose chemotherapy, the oral GI tract loses its ability to renew its lining, leading to inflammation (mucositis) and breakdown, causing nausea, vomiting and diarrhea that are refractory to available medications and require prolonged hospitalization. Severe oral GI toxicities can occur as frequently as 50% and cause profound misery to patients. The rates and severity increase with age and, thus, many older patients are turned away from the curative high dose therapy due to the risks of severe toxicities.
More on The Californer
About AB-205
AB-205 represents a new and unique approach to repairing damaged tissue through advanced cell-and-gene therapy. AB-205 consists of allogeneic (off-the shelf) 'universal' E-CEL® (human engineered cord endothelial) cells. Intravenous AB-205 is given after chemotherapy/radiation (high-dose therapy) conditioning and on the same day as autologous transplant. AB-205's immediate action repairs damaged tissue and thereby prevents (reduces) the extent of breakdown of tissues, which is the root cause of severe toxicities experienced by patients. Reducing or preventing severe toxicities means better quality of life and shorter stay in the hospital—i.e., savings to the healthcare system. AB-205 was recently granted both the Regenerative Medicine Advanced Therapy (RMAT) Designation and Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). Angiocrine is actively planning to advance AB-205 into a multi-center single registration Phase 3 trial based on the results of the Phase 1b/2 study.
About Angiocrine Bioscience, Inc.
Angiocrine Bioscience is a clinical-stage biotechnology company developing a radically new way to biologically repair damaged and diseased tissues and organs. Based on its novel and proprietary E-CEL® platform, Angiocrine is developing multiple E-CEL therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system; immune diseases that attack vessels, and ischemic diseases involving soft tissue, central nervous system and the heart.
More on The Californer
For additional information, please contact:
Angiocrine Bioscience, Inc.
John R. Jaskowiak
(877) 784-8496
[email protected]
SOURCE Angiocrine Bioscience, Inc.
Related Links
www.angiocrinebioscience.com
"Our investigators and Angiocrine are honored to be selected by ASH to present at its annual meeting this December," commented Paul Finnegan, MD, Angiocrine CEO. "We look forward to Dr. Michael Scordo's presentation of AB-205's efficacy and safety results from our Phase 1b/2 study as well as preparing for the upcoming Phase 3 registration study for this indication."
Session Name: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence I
Session Date: Saturday, December 5, 2020
Session Time: 7:30 AM - 9:00 AM ET
Presentation Time: 7:45 AM ET
About Severe Regimen-Related Toxicities
High-dose therapy and autologous hematopoietic cell transplantation is considered a standard-of-care method to cure aggressive systemic lymphoma. High dose therapy effectively eradicates cancer cells but also damages healthy tissue, which can lead to severe toxicities. Most affected is the lining of the oral-gastrointestinal (GI) tract. The oral GI tract renews its mucosal lining every 3 to 7 days. Because of the collateral damage from high dose chemotherapy, the oral GI tract loses its ability to renew its lining, leading to inflammation (mucositis) and breakdown, causing nausea, vomiting and diarrhea that are refractory to available medications and require prolonged hospitalization. Severe oral GI toxicities can occur as frequently as 50% and cause profound misery to patients. The rates and severity increase with age and, thus, many older patients are turned away from the curative high dose therapy due to the risks of severe toxicities.
More on The Californer
- New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
- Sonoma County's Largest Pop-up Used Book Sale Benefits Five Sonoma County Libraries
- Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)
- PropAccount.com Launches Marketing Hub Within PropGenie, Giving Prop Firm Operators an Automated Marketing Team
- Save 15 Percent Off Florida Keys Accommodations with KeysCaribbean's Advance Purchase Rate Discount
About AB-205
AB-205 represents a new and unique approach to repairing damaged tissue through advanced cell-and-gene therapy. AB-205 consists of allogeneic (off-the shelf) 'universal' E-CEL® (human engineered cord endothelial) cells. Intravenous AB-205 is given after chemotherapy/radiation (high-dose therapy) conditioning and on the same day as autologous transplant. AB-205's immediate action repairs damaged tissue and thereby prevents (reduces) the extent of breakdown of tissues, which is the root cause of severe toxicities experienced by patients. Reducing or preventing severe toxicities means better quality of life and shorter stay in the hospital—i.e., savings to the healthcare system. AB-205 was recently granted both the Regenerative Medicine Advanced Therapy (RMAT) Designation and Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). Angiocrine is actively planning to advance AB-205 into a multi-center single registration Phase 3 trial based on the results of the Phase 1b/2 study.
About Angiocrine Bioscience, Inc.
Angiocrine Bioscience is a clinical-stage biotechnology company developing a radically new way to biologically repair damaged and diseased tissues and organs. Based on its novel and proprietary E-CEL® platform, Angiocrine is developing multiple E-CEL therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system; immune diseases that attack vessels, and ischemic diseases involving soft tissue, central nervous system and the heart.
More on The Californer
- Woodside Rehab & Nursing Enters a New Era of Clinical Excellence and Growth
- Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
- Atticus Pharma Awarded $2 Million NIH Phase II SBIR Grant to Advance Cutaneous Lupus Drug Candidate
- Fall Jewellery Trends 2026: 3 Bracelets That Instantly Elevate Your Autumn Style
- iPOP! Alum Lucas Till Stars Alongside Zach Braff in Upcoming Film Clean Hands
For additional information, please contact:
Angiocrine Bioscience, Inc.
John R. Jaskowiak
(877) 784-8496
[email protected]
SOURCE Angiocrine Bioscience, Inc.
Related Links
www.angiocrinebioscience.com
Filed Under: Business
0 Comments
Latest on The Californer
- Home2 Suites by Hilton Lee's Summit, MO Opens to Guests
- Trick-or-Treat Along the El Dorado Nature Center Trails During Howl-o-ween Festival, Hosted by Long Beach Parks, Recreation and Marine
- Pervaziv AI Extends Cortex Cloud with Static and Runtime Security Across the Software Lifecycle
- Shanghai Chengwei Semiconductor Equipment Launches High Precision Laboratory Central Gas Supply System
- Auerbach International Surpasses 2 Billion Words Translated as It Marks 35 Years in Business
- Eddy Corp and SMAART POWER LLC Announce Strategic Teaming Agreement to Accelerate Microgrid and Distributed Energy Deployments
- California: Governor Newsom announces world-leading experts to deliver on his AI executive order, including advancing creation of a "kill switch"
- Your Local Pro Expands National Service Network to 273+ Locations Across Plumbing, Cleaning, Landscaping and Hydrovac
- Governor Newsom announces key step forward in California plan to link carbon markets with Washington State
- Wordly Turns Live Event Translation into Revenue Generator
- Acuvance Coker Study Finds Experience, Not Supply, Is the Biggest Advanced Practice Provider Workforce Challenge
- United Hotel Supply Expands Bulk FF&E Program as Hotel Owners Face Tightening PIP Deadlines
- eRacks Names Its Default Hypervisor: KVM on Ubuntu, Installed Since 2007, With eVirt Now Offered
- Omnigarde Climbs to #1 US Developer for Single Iris Accuracy in Global NIST IREX 10 Benchmark, Cutting Error Rates by Over 22%
- PQCrypto Appoints Manavendra Sial, Tenneco CFO, to Board of Directors
- Uk Financial Moonshot Token™ Robinhood-chain Goes Live On Tokpie Exchange Tomorrow, With Solana Side Of UKFLMS To Follow In Global Listing Expansion
- Long Beach City Council Approves Proclamation of Local Emergency to Prepare for Potential El Niño Impacts
- ClearanceIQ Launches AI-Powered CMMC Compliance Platform as Pentagon Suspends Phase 2
- City of Long Beach to Host Monster Mash Halloween Celebration at Lincoln Park
- Fresno Short Term Housing Leader Key Housing Announces Their Latest Featured Apartment Community